Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2004-03-12
2009-08-18
Kosar, Andrew D (Department: 1654)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C435S343000, C435S007230, C424S138100
Reexamination Certificate
active
07576188
ABSTRACT:
Aplidine and aplidine analogues are of use for the treatment of cancer, in particular in the treatment of leukemias and lymphomas, especially in combination therapies.
REFERENCES:
patent: 4493796 (1985-01-01), Rinehart
patent: 4670262 (1987-06-01), Battelli et al.
patent: 4952399 (1990-08-01), Lewenstein et al.
patent: 5294603 (1994-03-01), Rinehart
patent: 5462726 (1995-10-01), Lodge
patent: 5580871 (1996-12-01), Earl
patent: 5834586 (1998-11-01), Rinehart et al.
patent: 6030943 (2000-02-01), Crumb et al.
patent: 6034058 (2000-03-01), Rinehart et al.
patent: 6153731 (2000-11-01), Rinehart et al.
patent: 6156724 (2000-12-01), Rinehart et al.
patent: 6245759 (2001-06-01), Bilodeau et al.
patent: 6710029 (2004-03-01), Rinehart et al.
patent: RE39887 (2007-10-01), Rinehart et al.
patent: 2004/0010043 (2004-01-01), Lazaro et al.
patent: 2005/0004012 (2005-01-01), Mangues et al.
patent: 2006/0172926 (2006-08-01), Bertino et al.
patent: 0048149 (1982-03-01), None
patent: 0393883 (1990-10-01), None
patent: 2102322 (1997-07-01), None
patent: 78188 (2007-03-01), None
patent: WO 91/04985 (1991-04-01), None
patent: WO 93/00362 (1993-01-01), None
patent: WO 98/17275 (1998-04-01), None
patent: WO 98/17302 (1998-04-01), None
patent: WO 99/42125 (1999-08-01), None
patent: WO 00/20411 (2000-04-01), None
patent: WO-01/35974 (2001-05-01), None
patent: WO 01/36974 (2001-05-01), None
patent: WO 01/76616 (2001-10-01), None
patent: WO 02/02596 (2002-01-01), None
patent: WO 02/30441 (2002-04-01), None
patent: WO 03/033013 (2003-04-01), None
patent: WO 2004/080421 (2004-09-01), None
da Rocha, 2001, Current Opinion in Pharmacology, 1, 364-369.
Ady-Vago, N. et al., “L-Carnitine as a Protector Against Aplidine Induced Skeletal Muscle Toxicity,” Proceedings of the American Association for Cancer Research, vol. 42, pp. 545 (Mar. 2001).
Bergeron, Raymond J. et al., “Antineoplastic and Antiherpetic Activity of Spermidine Catecholamide Iron Chelators,” Biochemical and Biophysical Research Communications, vol. 121, No. 3, 848-854, 1984.
Chapa, AM. et al., “Influence of Intravenous L-Carnitine Administration In Sheep Preceding an Oral Urea Drench.” Journal of Animal Science, vol. 76, No. 11, pp. 2930-2937, 1998.
Depenbrock, H. et al., “In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic-precursor cells,” British Journal of Cancer, vol. 78, No. 6, 739-744, 1998.
Erba, E. et al., “Cell cycle phases perturbations induced by new natural marine compounds,” Annals of Oncology ,vol. 7, Supplement 1, #283, pp. 82, 1996.
Faircloth, G. et al., “Aplidine (APL) is a novel marine-derived depsipeptide with in vivo antitumor activity,” Proceedings of the American Association for Cancer Research. vol. 39, #1551, pp. 227, 1998.
Faircloth, G. et al., “Dehydrodidemnin B (DDB) a new marine derived anti-cancer agent (MDA) with activity against experimental tumor models” and Biological activity of thiocoraline. A new depsipeptide from a marine micromonospora,° Annals of Oncology. vol. 7, Supplement 1, #111 and #112, pp. 34, 1996.
Faircloth, G. et al., “Preclinical characterization of Aplidine (APD), a new marine anticancer depsipeptide (MADEP),” Proceedings of the American Association for Cancer Research, vol. 38, #692, pp. 103, 1997.
Faircloth, G. et al., “Preclinical development of aplidine, a novel marine-derived agent with potent antitumor activity,” Annals of Oncology, vol. 9, Supplement 2, #129, pp. 34, 1998.
Faircloth, G. et al., Schedule-dependency of aplidine, a marine depsipeptide with antitumor activity, ° Proceedings of the American Association for Cancer Research, vol. 40, #2612, pp. 394-395, 1999.
Geldorf, Albert A. et al., “Cytotoxicity and neurocytotoxicity of new marine anticancer agents evaluated using in vitro assays,” Cancer Chemother. Pharmacol. vol. 44, pp. 312-318, 1999.
Genin, Michael J. et al., “Synthesis and Crystal Structure of a Peptidomimetic Containing the (R)-4, 4-Spiro Lactam Type-II β-Turn Mimic,” Journal of Organic Chemistry, vol. 58, No. 8, pp. 2334-2337, 1993.
Gomez-Fabre; P.M. et al., “Polamine contents of human breast cancer cells treated with the cytotoxic agents chlorpheniramine and dehydrodidemnin B,” Cancer Letters, vol. 113, Nos. 1,2 pp. 141-144, 1997.
Goodman & Gilman's, The Pharacological Basis of Therapeutics, 9thed., Calabresi et al., Section X, Chemotherapy of Neoplastic Diseases, pp. 1225-1229, 1996.
Hamada et al., “Efficient Total Synthesis of Didemnins A and B”, J. Am. Chem. Soc., vol. 111, pp. 669-673 (Jan. 18, 1989).
Jacob L. “General Pharmacologic Principles”, Pharmacology (Fourth Edition). Williams and Wilkins Company, 1996. pp. 1-13.
Jiang et al. “Antitumor Activity of Didemnin B in the Human Tumor Stem Cell Assay”. Cancer Chemotherapy and Pharmacology, 1983. 11:1-4.
Jou, Gemma et al., “Total Synthesis of Dehydrodidemnin B. Use of Uronium and Phosphonium Salt Coupling Reagents in Peptide Synthesis in Solution,” Journal of Organic Chemistry vol. 62, No. 2, pp. 354-366, 1997.
Jouin et al. “Antineoplastic Activity of Didemnin Congeners: Nordidemnin and Modified Chain Analogues”. Journal of Medicinal Chemistry. 1991, 34:486-491.
Lobo, C. et al., “Effect of Dehydrodidemnin B on Human Colon Carcinoma Cell Lines,” Anticancer Research vol. 17. No. 1A, pp. 333-336, 1997.
Mastbergen et al., “Cytotoxicity and Neurocytotoxicity of Aplidine, a New Marine Anticancer Agent Evaluated Using In vitro Assays,” Annals of Oncology, vol. 9, suppl. 2, #131, 1998.
Montgomery et al., Fed. Prac., vol. 44, p. 634 (1987).
Montgomery, D. W., Zukoski, C. F., Transplantation, vol. 40, pp. 49-56 (1985).
Nujien B. et al., Pharmaceutical development of Anticancer Agents derived from Marine Sources, Anti-Cancer Drugs, vol. 11, pp. 793-811, 2000.
Osol A. [Editor] “Chapter 27: Structure-Activity Relationship and Drug Design”. Remington's Pharmaceutical Sciences (Sixteenth Edition), 1980. pp. 420-435.
Raymond, Eric et al., “Preliminary Results of a Phase I and Pharmacokinetic Study of Aplidine Given as a 24-hour Infusion Every Weeks in Patients with Solid Tumors and Non Hodgkin's Lymphomas,” Proceedings of the American Association for Cancer Research, vol. 41, #3886, 2000.
Rinehart, Kenneth L. et al., “Didemnins and Tunichlorin: Novel Natural Products from the Marine Tunicate Trididemnum Solidum,” Journal of Natural Products. vol. 51, No. 1, pp. 1-21, 1988.
Rinehart, Kenneth L., Jr. et al., “Didemnins: Antiviral and Antitumor Depsipeptides from a Caribbean Tunicate,” Science, vol. 212, No. 4497, pp. 933-935, 1981.
Rinehart, Kenneth L., Jr. et al., “Antiviral and antitumor compounds from tunicates,” Federation Proceedings;vol. 42, No. 1, pp. 87-90 1983.
Rinehart, Jr. et al., Pure and Appl. Chem., vol. 54, pp. 2409-2424 (1982).
Rinehart, “Didemnin and its Biological Properties”, Escom, pp. 626-631, (1987).
Rinehart, Jr., J. Am. Chem. Soc. vol. 103, pp. 1857-1859 (1981).
Rinehart et al., “Total Synthesis of Didemnins, A, B, and C”, J. Am. Chem. Soc., vol. 109, pp. 6846-6848 (Oct. 28, 1987).
Sakai et a;., “Structure-Activity Relationships of the Didemnins,” Journal of Medicinal Chemistry, vol. 39, No. 14, pp. 2819-2834, 1996.
Schmidt et al., “Total Synthesis of the Didemnins-2. Synthesis of Didemnin A, B, C, and Prolyldidemnin A”, Tetrahedron Letters, vol. 29, pp. 4407-4408 (1988).
Seebach et al., “Alkylation of Amino Acids Without Loss of the Optical Activity: Preparation of α-Substituted Proline Derivatives. A Case of Self-Reproduction of Chiralty,” Journal of the American Chemical Society, vol. 105, No. 16, pp. 5390-5398, 1983.
The Merck Index, Eleventh Ed., p. 489 (1989).
Urdlales et al., “A
Barnejee Debabrata
Bertino Joseph R.
Faircloth Glynn Thomas
Guray Saydam
Jimeno José
Gudibande Satyanarayana R
King & Spalding LLP
Kosar Andrew D
Pharma Mar, S.A.U.
Sonnenfeld Kenneth H.
LandOfFree
Antitumoral treatments does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antitumoral treatments, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antitumoral treatments will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4091441